Synergistic pandemics: Confronting the global HIV and tuberculosis epidemics

Clinical Infectious Diseases

Volumn 50, Issue SUPPL. 3, 2010, Pages

  Mayer, Kenneth H ^a,b   Hamilton, Carol Dukes ^c  

^a MIRIAM HOSPITAL   (United States)

^b FENWAY INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; EDITORIAL; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; PANDEMIC; PRIORITY JOURNAL; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; DISEASE OUTBREAKS; HIV INFECTIONS; HUMANS; TUBERCULOSIS;

EID: 77951829408     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651475     Document Type: Editorial

References (26)

1. Gray RH. Biomedical prevention including microbicides, vaccines, circumcision and PrEP. In: Program and abstracts of the 5th IAS Conference on HIV Pathogenesis and Treatment (Cape Town). 2009. Abstract TUPL101.
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
3. Bassett IV, Walensky RP. Integrating HIV screening into routine health care in resourcelimited settings. Clin Infect Dis 2010; 50(Suppl 3):S77-S84 (in this supplement).
4. Grant RM. Antiretroviral agents used by HIVuninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis 2010; 50(Suppl 3):S96-S101 (in this supplement).
5. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis 2010; 50(Suppl 3):S85-S95 (in this supplement).
6. DeGruttola V, Smith DM, Little SJ, Miller V. Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clin Infect Dis 2010; 50(Suppl 3): S102-S107 (in this supplement).
7. Beyrer CB. Global prevention of HIV infection for neglected populations: men who have sex with men. Clin Infect Dis 2010; 50(Suppl 3): S108-S113 (in this supplement).
8. Vlahov D, Robertson AM, Strathdee SA. Prevention of HIV infection among injection drug users in resource-limited settings. Clin Infect Dis 2010; 50(Suppl 3):S114-S121 (in this supplement).
9. Abdool Karim Q, Sibeko S, Baxter C. Preventing HIV infection in women: a global health imperative. Clin Infect Dis 2010; 50(Suppl 3):S122-S129 (in this supplement).
10. Mofenson LM. Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection. Clin Infect Dis 2010; 50(Suppl 3):S130-S148 (in this supplement).
11. Vermund SH, Hodder SL, Justman JE, et al. Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis 2010; 50(Suppl 3):S149-S155 (in this supplement).
12. Jassal MS, Bishai WR. Epidemiology and challenges to the elimination of global tuberculosis. Clin Infect Dis 2010; 50(Suppl 3): S156-S164 (in this supplement).
13. Burman WJ. Rip Van Winkle wakes up: drug development of tuberculosis treatment in the 21st century. Clin Infect Dis 2010; 50(Suppl 3):S165-S172 (in this supplement).
14. Dorman SE. New diagnostic tests for tuberculosis: bench, bedside, and beyond. Clin Infect Dis 2010; 50(Suppl 3):S173-S177 (in this supplement).
15. Beresford B, Sadoff JC. Update on research and development pipeline: tuberculosis vaccines. Clin Infect Dis 2010; 50(Suppl 3): S178-S183 (in this supplement).
16. Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis 2010; 50(Suppl 3):S184-S194 (in this supplement).
17. Cegielski JP. Extensively drug-resistant tuberculosis: there must be some kind of way out of here. Clin Infect Dis 2010; 50(Suppl 3): S195-S200 (in this supplement).
18. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: The epidemiology and the response. Clin Infect Dis 2010; 50(Suppl 3):S201-S207 (in this supplement).
19. Granich R, Akolo C, Gunneberg C, Getahun H, Williams P, Williams B. Prevention of tuberculosis in people living with HIV. Clin Infect Dis 2010; 50(Suppl 3):S215-S222 (in this supplement).
20. Bekker L-G, Wood R. The changing natural history of tuberculosis and HIV coinfection in an urban area of hyperendemicity. Clin Infect Dis 2010; 50(Suppl 3):S208-S214 (in this supplement).
21. Sterling TR, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis 2010; 50(Suppl 3):S223-S230 (in this supplement).
22. Shenoi SV, Escombe AR, Friedland G. Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts. Clin Infect Dis 2010; 50(Suppl 3): S231-S237 (in this supplement).
23. Chamie G, Luetkemeyer A, Charlebois E, Havlir DV. Tuberculosis as part of the natural history of HIV infection in developing countries. Clin Infect Dis 2010; 50(Suppl 3):S245-S254 (in this supplement).
24. Howard AA, El-Sadr WM. Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned. Clin Infect Dis 2010; 50(Suppl 3):S238-S244 (in this supplement).
25. Coggin WL, Ryan CA, Holmes CB. Role of the US President's Emergency Plan for AIDS Relief in responding to tuberculosis and HIV coinfection. Clin Infect Dis 2010; 50(Suppl 3): S255-S259 (in this supplement).
26. Harrington M. From HIV infection to tuberculosis and back again: a tale of activism in 2 pandemics. Clin Infect Dis 2010; 50(Suppl 3): S260-S266 (in this supplement).